We are a passionate group of like-minded individuals, all contributing to our vision of whole genome sequencing (WGS)-based diagnostic testing becoming the standard of care. Our mission is to deliver comprehensive, cost-effective genomic testing to patients using WGS.
Our story began in 2014, when our founders teamed up to bring the then emerging technology of WGS into widespread use in the clinic. Foreseeing its potential to become the standard of diagnostic care, they poured their collective expertise in algorithm development, data interpretation and systems automation into developing a platform to efficiently and effectively process and analyze the large amounts of complex data generated by WGS.
The result is our proprietary Genomic Intelligence® platform.
Today, the platform is the foundation of the WGS-based testing performed within our CLIA-certified, CAP-accredited lab. It’s unique capability to detect small sequence changes, structural variants, mitochondrial variants and tandem repeat expansions within a single assay enables our clinical team to provide rare disease patients with better insights into the molecular cause behind their clinical symptoms. Oftentimes ending years’ long diagnostic odysseys. It additionally enables comprehensive genomic screening for healthy individuals seeking insight into the influence their DNA may have on their future health or the health of their children.
Our Genomic Intelligence® platform is also the foundation of NGS-based testing performed by a growing number of hospital and commercial labs.
We are the true whole genome company.
Meet Our Team
Meet our leadership team who is as raising awareness of the benefits of WGS-based testing for patients and driving its adoption in the clinic.